Bispecific antibody · Immune activation, directed at delta-like protein 3 (DLL3) and T-cell surface glycoprotein CD3 · developed by AbbVie
Alveltamig is a trispecific T-cell engaging antibody that binds two different epitopes of DLL3, a Notch pathway protein overexpressed on various cancer cells, and CD3 on cytotoxic T-lymphocytes. It redirects these T-cells to kill DLL3-expressing tumor cells. It is being studied in extensive-stage small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
Extensive Stage-Small Cell Lung Cancer (ES-SCLC)
See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ABBV catalysts and pipeline →